Pfizer Inc.
PD-1/PD-L1 INHIBITORS FOR THE TREATMENT OF CANCER
Last updated:
Abstract:
The invention relates to methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an inhibitor of the interaction between the PD-1 receptor and its ligand PD-L1.
Status:
Application
Type:
Utility
Filling date:
5 Aug 2020
Issue date:
19 Nov 2020